Session Chair Profile

Ph.D., Vice Chancellor for Science Policy and Strategy, UCSF; Director, UCSF Precision Medicine; Professor, Cellular & Molecular Pharmacology, UCSF

Biography
Dr. Yamamoto is a leader in science and public policy. He has made an indelible impact by simultaneously advocating for Precision Medicine across the .edu, .gov, .com and .org sectors. As Chair of the National Academies Board on Life Sciences, he appointed and served on the study committee that produced “Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease”, the report that enunciated the precision medicine concept. He helped to stimulate President Obama’s interest, which led to the Precision Medicine Initiative, as well as Gov. Jerry Brown’s launch of the California Initiative to Advance Precision Medicine. He also promoted a precision medicine approach to Vice President Biden’s Cancer Moonshot, provoked broader participation by the corporate and nonprofit sectors, and directs UCSF Precision Medicine, an institution-wide imperative. In addition, Dr. Yamamoto has led or served on numerous federal or national committees focused on public and science policy, public understanding and support of biological research, research funding and peer review, and science education and the biomedical workforce; he chairs the Coalition for the Life Sciences, and sits on the National Academy of Medicine Council and Executive Committee, and the National Academy of Sciences Division of Earth and Life Studies Advisory Committee. He is a member of the Advisory Board for Lawrence Berkeley National Laboratory and the Board of Directors and Executive Committee of Research!America. At UCSF, Dr. Yamamoto is vice chancellor for science policy and strategy and professor of cellular and molecular pharmacology. He is a leading researcher, investigating transcriptional regulation by nuclear receptors, which mediate the actions of essential hormones and cellular signals; he uses mechanistic and systems approaches to pursue these problems in pure molecules, cells and whole organisms. He is an elected member of the National Academy of Sciences, the National Academy of Medicine, the American Academy of Arts and Sciences, and the American Academy of Microbiology, and a fellow of the American Association for the Advancement of Science.


 Session Abstract – PMWC 2022 Silicon Valley


  • UC Precision Medicine Programs: Achievements and Challenges
    Session Chair: India Hook-Barnard, EBRC
    - Keith Yamamoto, UCSF
    - Clara Lajonchere, UCLA
    - Frederick J Meyers, UC Davis Health
  • Fireside Chat with Conrad Vial, Sutter Health and Precision Medicine Practices
    - Conrad Vial, Sutter Health
    - Erika Vial-Monteverdi, RotaCare Clinics
  • Precision Approaches to Chronic Disease (PANEL)
    Session Chair: Jennifer Lovejoy, Seven.me
    - Noel Mueller, Johns Hopkins
    - Maureen K. O'Connor, ZealCare
    - Sunjya K. Schweig, California Center For Functional Medicine (CCFM)
  • DNA-based Weight Loss Interventions: What Have We Learned? (PANEL)
    Session Chair: Jennifer Lovejoy, Seven.me
    - George Bray, Pennington Biomedical Research Center
    - Christopher Gardner, Stanford
  • Advances in Digital Health, Diabetes and Obesity Management (PANEL)
    Session Chair: Mike Snyder, Stanford
    - Jessilyn Dunn, Duke University
    - Jonathan Long, Stanford
    - James Galagan, Boston University
  • Illumina Accelerator Innovation
    Session Chair: Amanda Cashin, Illumina Accelerator
    - Trevor Levin, Convergent Genomics
    - Rhidi Tariyal, NextGen Jane
    - Kareem Barghouti, VastBiome
  • PMWC Showcase
    - Jarret Glasscock, Cofactor Genomics
    - David Hanna, Thermo Fisher

 Session Abstract – PMWC 2022 Silicon Valley


Track Chair:
Keith Yamamoto, UCSF

Patient-centric data – Real-World Evidence (RWE) and Real-World Data (RWD) - is becoming instrumental in the drug development process and for health care decisions in general. This data is not only informative for the process from discovery to new indications, clinical trial design, and drug development, it also can be of value to monitor post-marketing drug safety and for decision support in clinical practice. As the data becomes a decision driver, science companies and medical organizations are increasingly focused on leveraging RWD and RWE to not only better understand the patient populations using their drugs and the respective outcomes, but also to accelerate clinical decision support. This session will focus on the various aspects of integrating RWE and RWD to support drug development and clinical decision support

Sessions:

  • Realizing the Promise of Precision Medicine Using Real-world Evidence (PANEL)
    Session Chair: Atul Butte, UCSF
    - Nancy A. Dreyer, IQVIA
    - Mark Laabs, RCRF
    - Rhonda Cooper-DeHoff, University of Florida
  • Opportunities and Challenges in Using Real World Data (RWD) (PANEL)
    Session Chair: Vivek Rudrapatna, UCSF
    - Joseph Wu, Stanford University
  • How Are Patient Data Revolutionizing Precision Medicine? (PANEL)
    Session Chair: Clara Lajonchere, UCLA
    - Sharon Terry, Genetic Alliance
    - Farid Vij, Invitae
    - Latha Palaniappan, Stanford
  • Regulatory Requirements and Challenges for Using RWE
    Session Chair: Sheila Walcoff, Goldbug Strategies
    - Kathy Hibbs, 23andMe
  • Government Partnerships: California Initiative to Advance Precision Medicine
    Session Chair: Julianne McCall, California Initiative to Advance Precision Medicine
    - William Kim, UCSD
    - George M. Slavich, UCLA
  • Leveraging RWE to Create Value (PANEL)
    Session Chair: Kathryn A. Phillips, UCSF
    - Phil Febbo, Illumina
    - Suzanne Belinson, Tempus
    - Stacey Dacosta Byfield, OptumLabs
  • Computational Social Choice Theory's Impact on the Collection and Understanding of RWD
    - Ian Terry, LunaDNA
  • The Past, Present, and Future of RWE
    Session Chair: Keith Yamamoto, UCSF
    - Matthew Porteus, Stanford